Information Provided By:
Fly News Breaks for February 21, 2020
Feb 21, 2020 | 06:23 EDT
Wells Fargo analyst Yanan Zhu initiated coverage of Editas Medicine with an Equal Weight rating and $28 price target. While Editas has the industry's most advanced Crisper genome editing platform and a highly competitive sickle cell disease program, there is "potentially under-appreciated technical risk" to its lead clinical program targeting Leber Congenital Amaurosis-10 and extended timelines to data from the sickle cell program, Zhu tells investors in a research note. As such, the analyst sees the stock as fairly valued.
News For EDIT From the Last 2 Days
There are no results for your query EDIT